




| | | |
|---|------------------------|-----------------------------|
| TRANSMITTAL FORM MAY 12 2005 (to be used for all correspondence after initial filing) | Application Number | 09/806,657 |
| | Filing Date | October 4, 1999 |
| | First Named Inventor | Peter Bernstein |
| | Art Unit | Not Yet Assigned |
| | Examiner Name | Not Yet Assigned |
| Total Number of Pages in This Submission | Attorney Docket Number | ASZN0017-100 (Z70402-1P US) |

| ENCLOSURES (check all that apply) | | |
|--|---|--|
| <input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input checked="" type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD | <input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): - Table A - Statement Under 37 CFR 3.73(b) - executed Assignment - Return Postcard |
| Remarks | | |

| SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT | | | |
|--|---|----------|--------|
| Firm | Cozen O'Connor, P.C. | | |
| Signature |  | | |
| Printed Name | Paul K. Legaard | | |
| Date | 10 MAY 2005 | Reg. No. | 38,534 |

| CERTIFICATE OF TRANSMISSION/MAILING | | | |
|---|---|------|-------------|
| I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. | | | |
| Signature |  | | |
| Typed or printed name | Paul K. Legaard | Date | 10 MAY 2005 |

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED
MAY 18 2005
TECH CENTER 1600/2900 #11
HKO
5-26-05

Sir:

**POWER OF ATTORNEY WITH REVOCATION AND
CHANGE OF CORRESPONDENCE ADDRESS**

I hereby revoke all previous powers of attorney or authorizations of agent given in the applications identified in Table A attached hereto, and appoint

☒ Practitioners at Customer Number: 52286

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please change the Correspondence Address for all applications identified in Table

A to:

☒ Practitioners at Customer Number: 52286

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. (A statement under 37 CFR 3.73(b) is enclosed.)

Respectfully submitted,
ASTRAZENECA AB

Date: 13 April 2005

By: Christer Wahlström

Name: Christer Wahlström

Title: Director Patent Operations



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED
MAY 18 2005
TECH CENTER 1600/2900

Sir:

STATEMENT UNDER 37 CFR 3.73(b)

Applicant, **AstraZeneca AB**, a corporation, states that it is:

☒ the assignee of the entire right, title, and interest of the applications identified in Table A attached hereto.

The extent (by, percentage) of its ownership interest is **100%** in the patent applications identified in Table A by virtue of:

☒ a copy of the pertinent assignment from the inventor(s) of the patent applications identified in Table A is enclosed herewith.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Respectfully submitted,

ASTRAZENECA AB

Date: 13 April 2005

By: Christer Wahlström

Name: Christer Wahlström

Title: Director Patent Operations

ASSIGNMENT

For good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR(S),

BERNSTEIN, Peter, Robert; DEDINAS, Robert, Frank; OHNMACHT, Cyrus, John; RUSSELL, Keith; SHERWOOD, Scott, Alan; of 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437, US; 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437, US; 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437, US; and 135 D Highland Boulevard, New Castle, DE 19720, US, respectively, citizens of the United States, the United States, the United States, the United Kingdom and the United States, respectively.

hereby sell(s), assign(s) and transfer(s) to ASSIGNEE, AstraZeneca AB, a company created and existing under the laws of Sweden having its Head Office at S-151 85 Sodertalje, Sweden, and the successors, assigns and legal representatives of the ASSIGNEE the entire right, title and interest for the United States and its territorial possessions and in all foreign countries in and to, any and all improvements which are disclosed in the invention entitled: NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS

and which is found in

- (a) ___ U.S. patent application executed on even date herewith;
- (b) ___ U.S. patent application executed on _____;
- (c) ___ U.S. application serial no. filed on _____;
- (d) X International application no. PCT/GB99/03274 filed on 4 October 1999

and any legal equivalent thereof in a foreign country, including the right to claim priority and, in and to, all Letters Patent to be obtained for said invention by the above application or any continuation, division, renewal, or substitute thereof, and as to Letters Patent any reissue or reexamination thereof;

ASSIGNOR(S) hereby covenant(s) that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment;

ASSIGNOR(S) further covenant(s) that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, litigation, or proceeding related thereto and will promptly execute and deliver to ASSIGNEE or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof. An attorney of record is authorized and requested by the execution of this assignment to insert into this assignment the filing date and serial number of said application when officially known.

Signed this

29 day of March, 2001

Peter Robert Bernstein
Peter Robert Bernstein

WITNESS: Frances Koubek

DATE: 29 MARCH 2001

WITNESS: Anzla Khatky

DATE: 29 March 2001



Additional page(s) are attached hereto.

29 day of March, 2001

Robert Frank Dedinas
Robert Frank Dedinas

WITNESS: Francis Tomkins
DATE: 29 MARCH 2001

WITNESS: Angela Katty
DATE: 29 March 2001

29 day of March, 2001

Cyrus John Ohnmacht
Cyrus John Ohnmacht

WITNESS: Francis Tomkins
DATE: 29 March 2001

WITNESS: Angela Katty
DATE: 29 March 2001

29 day of March, 2001

Keith Russell
Keith Russell

WITNESS: Francis Tomkins
DATE: 29 MARCH 2001

WITNESS: Angela Katty
DATE: 29 March 2001

____ day of _____, 2001

Scott Alan Sherwood

WITNESS: _____

DATE: _____

WITNESS: _____

DATE: _____

☐ Additional page(s) are attached hereto.

ASSIGNMENT

For good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR(S),

BERNSTEIN, Peter, Robert; DEDINAS, Robert, Frank; OHNMACHT, Cyrus, John; RUSSELL, Keith; SHERWOOD, Scott, Alan; of 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437, US; 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437, US; 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437, US; 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437, US; and 135 D Highland Boulevard, New Castle, DE 19720, US, respectively, citizens of the United States, the United States, the United States, the United Kingdom and the United States, respectively.

hereby sell(s), assign(s) and transfer(s) to ASSIGNEE, AstraZeneca AB, a company created and existing under the laws of Sweden having its Head Office at S-151 85 Sodertalje, Sweden, and the successors, assigns and legal representatives of the ASSIGNEE the entire right, title and interest for the United States and its territorial possessions and in all foreign countries in and to, any and all improvements which are disclosed in the invention entitled: NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS

and which is found in

- (a) ___ U.S. patent application executed on even date herewith;
- (b) ___ U.S. patent application executed on _____;
- (c) ___ U.S. application serial no. filed on _____
- (d) ☒ International application no. PCT/GB99/03274 filed on 4 October 1999

and any legal equivalent thereof in a foreign country, including the right to claim priority and, in and to, all Letters Patent to be obtained for said invention by the above application or any continuation, division, renewal, or substitute thereof, and as to Letters Patent any reissue or reexamination thereof;

ASSIGNOR(S) hereby covenant(s) that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment;

ASSIGNOR(S) further covenant(s) that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, litigation, or proceeding related thereto and will promptly execute and deliver to ASSIGNEE or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof. An attorney of record is authorized and requested by the execution of this assignment to insert into this assignment the filing date and serial number of said application when officially known.

Signed this

_____ day of _____, 2001

Peter Robert Bernstein

WITNESS: _____

WITNESS: _____

DATE: _____

DATE: _____

☒ Additional page(s) are attached hereto.

____ day of _____, 2001

Robert Frank Dedinas

WITNESS: _____

WITNESS: _____

DATE: _____

DATE: _____

____ day of _____, 2001

Cyrus John Ohnmacht

WITNESS: _____

WITNESS: _____

DATE: _____

DATE: _____

____ day of _____, 2001

Keith Russell

WITNESS: _____

WITNESS: _____

DATE: _____

DATE: _____

☒ Additional page(s) are attached hereto.

27th day of March, 2001

Scott Alan Sherwood
Scott Alan Sherwood

WITNESS: Thomas S. Senkevich
DATE: MARCH 27, 2001

WITNESS: Joselyn Senkevich
DATE: March 27, 2001




TABLE A

| Our Ref. AstraZeneca Ref. | Serial No. Filing Date | First Inventor | Examiner Art Unit | Title |
|------------------------------|---------------------------|----------------|------------------------------|--|
| ASZN0005-100 100368-1P US | 10/477,851 5/16/02 | Brown | Rita J. Desai 1625 | 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide Derivatives And Their Use For The Treatment Of Pain, Anxiety Or Gastrointestinal Disorders |
| ASZN0005-101 100369-1P US | 10/477,854 5/16/02 | Brown | Celia C. Chang 1625 | 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide Derivatives And Their Use For The Treatment Of Pain, Anxiety Or Gastrointestinal Disorders |
| ASZN0005-102 100372-1P US | 10/477,853 5/16/02 | Brown | Rita J. Desai 1625 | 4-(Phenyl-(piperidin-4-yl)-amino)-benzamide Derivatives And Their Use For The Treatment Of Pain, Anxiety Or Gastrointestinal Disorders |
| ASZN0005-103 100373-1P US | 10/477,633 5/16/02 | Brown | Rita J. Desai 1625 | 4-(phenyl-(piperidin-4yl)-amino)-benzamide Derivatives And Their Use For The Treatment Of Pain, Anxiety Or Gastrointestinal Disorders |
| ASZN0005-104 100375-1P US | 10/477,636 5/16/02 | Brown | Rita J. Desai 1625 | 4-(phenyl-(piperidin-4yl)-amino)-benzamide Derivatives And Their Use For The Treatment Of Pain, Anxiety Or Gastrointestinal Disorders |
| ASZN0006-100 100514-1P US | 10/497,565 12/11/02 | Leung | Not Yet Assigned | Benzodiazepine Derivatives, Preparation Thereof And Use Thereof |
| ASZN0007-100 100590-1P US | 10/498,864 12/17/02 | Cheng | Not Yet Assigned | Therapeutic Heterocycles |
| ASZN0008-100 100100-1P US | 10/333,669 1/21/03 | Patel | Raymond K. Covington 1625 | Process For Asymmetric Synthesis Of Substituted 1,4-Dihydropyridines |
| ASZN0009-100 100102-1P US | 10/333,654 9/5/03 | Patel | Alton N. Pryor 1616 | Process For Synthesis Of Alpha,Beta-unsaturated Ketones |

| | | | | |
|------------------------------|------------------------|-------------|-------------------------------|--|
| ASZN0010-100 100541-1P US | 10/494,387 4/30/04 | Bialecki | Raymond J. Henley III 1614 | Method For The Treatment Of Overactive Bladder |
| ASZN0010-101 100542-1P US | 10/494,195 11/1/02 | Bialecki | Not Yet Assigned | Compounds And Method For The Treatment Of Overactive Bladder |
| ASZN0011-100 100570-1P US | 10/502,191 1/23/03 | Jones | D. Margaret M. Seaman 1625 | Method |
| ASZN0012-100 100186-1P US | 10/415,853 11/3/03 | Chapdelaine | Not Yet Assigned 1614 | N-type Calcium Channel Antagonists For The Treatment Of Pain |
| ASZN0012-101 100463-1P US | 10/488,066 8/9/04 | D'Amico | D. Margaret M. Seaman 1625 | N-type Calcium Channel Antagonists For The Treatment Of Pain |
| ASZN0012-102 100464-1P US | 10/488,025 8/23/02 | D'Amico | Not Yet Assigned | N-type Calcium Channel Antagonists For The Treatment Of Pain |
| ASZN0013-100 Z70624-1P US | 10/168,758 11/25/02 | Chapdelaine | Maury A. Audet 1654 | Cd45 Inhibitors |
| ASZN0013-101 Z70626-1P US | 10/168,477 11/25/02 | Chapdelaine | Kevin Weddington 1614 | Cd45 Inhibitors |
| ASZN0014-100 100121-1P US | 10/333,658 7/31/01 | Bernstein | Shailendra Kumar 1621 | N-(2-phenyl-3-aminopropyl)naphthamides |
| ASZN0015-100 100174-1P US | 10/381,755 3/26/03 | Bernstein | Bruck Kifle 1624 | Cyclized Benzamide Neurokinin Antagonists For Use Therapy |
| ASZN0016-100 100237-1P US | 10/450,284 12/20/01 | Shenvi | Celia C. Chang 1625 | Compounds |

| | | | | |
|------------------------------|-----------------------|-----------|------------------|--|
| ASZN0017-100 Z70402-1P US | 09/806,657 10/4/99 | Bernstein | Not Yet Assigned | Naphthalenecarboxamides As Tachykinin Receptor Antagonists |
| ASZN0018-100 100003-2P US | 11/042,752 1/24/05 | Albert | Not Yet Assigned | Neurokinin Antagonists For Use As Medicaments |
| ASZN0019-100 100848-1P US | 10/528,640 10/2/03 | Becker | Not Yet Assigned | Novel Lactams And Uses Thereof |